top of page

GPCR News 

Post: Blog2_Post

VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron

December 2021


Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery.

VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. "

Read more at the source

#DrGPCR #GPCR #IndustryNews

1 view0 comments

Recent Posts

See All

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin